Heart failure and atrial fibrillation: Current concepts and controversies

Heart

Volumn 77, Issue 4, 1997, Pages 309-313

  Van Den Berg, Maarten P ^a   Tuinenburg, Anton E ^a   Crijns, Harry J G M ^a   Van Gelder, Isabelle C ^a   Gosselink, A T Marcel ^a   Lie, Kong I ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atrial fibrillation; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; INOTROPIC AGENT;

CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 0030998256     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.77.4.309     Document Type: Review

References (38)

1. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure. Circulation 1993;88:107-15.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982;306:1018-22.
3. Likoff MJ, Chandler SL, Kay KR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987;59:634-8.
4. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomopathy assessed for cardiac transplantation. Am J Cardiol 1990;65:903-8.
5. Middlekauf HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991;84:40-8.
6. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farell L, Cohn JN, for the V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. Circulation 1993;87(suppl VI):102-10.
7. Hofmann T, Meinertz T, Kasper W, Geibel A, Zehender M, Hohnloser S, et al. Mode of death in idiopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. Am Heart J 1988;116:1455-63.
8. Van Gelder IC, Crijns HJGM, Tieleman RG, Hillege HJ, Gosselink ATM, Lie KI. Mortality in patients with atrial fibrillation is related to the severity of the underlying disease and not to the arrhythmia [abstract]. Circulation 1994;90(suppl I):541.
9. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
10. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994;89:724-30.
11. Van Gelder IC, Crijns HJGM, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68:41-6.
12. Solti F, Vescey T, Kékesi V, Juhàsz-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 1989;23:882-6.
13. Isobe F, Schuessler RB, Mitsuno M, Nitta T, Cronin CS, Boineau JP, et al. High atrial pressure directly affects the dispersion of refractoriness and the inducibility of atrial fibrillation [abstract]. Circulation 1993;88(suppl I):326.
14. Klein LS, Miles WM, Zipes DP. Effect of atrioventricular interval during pacing or reciprocating tachycardia on atrial size, pressure, and refractory period. Contraction-excitation feedback in the human atrium. Circulation 1990;82:60-8.
15. Van Den Berg MP, Crijns HJGM, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Cardiac Failure 1995;1:355-64.
16. Gosselink ATM, Crijns HJGM, Hamer HPM, Hillege HJ, Lie KI. Changes in left and right atrial size after cardioversion of atrial fibrillation: role of mitral valve disease. J Am Coll Cardiol 1993;22:1666-72.
17. Coumel P. Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial fibrillation. Mechanisms and management. New York: Raven Press, 1992:109-25.
18. Van Den Berg MP, Venema AW, Crijns HJGM, Heesen WF, Brouwer J, Lie KI. Clinical and electrocardiographic correlates of exercise-induced atrial fibrillation: a case-control study. Am J Noninvas Cardiol 1994;8:146-50.
19. Pinto YM, Buikema JH, Van Gilst WH. Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses. Clin Exp Hypertens 1995;17:441-68.
20. Borzak S, Goldstein S, Sabbah HN. Hemodynamic and neurohumoral predictors of the development of atrial fibrillation in dogs with chronic heart failure [abstract]. Circulation 1993;88(suppl I):18.
21. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-3.
22. Rosenqvist M, Lee MA, Moulinier L, Springer MJ, Abbott JA, Wu J, et al. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J Am Coll Cardiol 1990;16:1467-74.
23. Heinz G, Siostrzonek P, Kreiner G, Gössinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol 1992;69:489-92.
24. Rodriguez LM, Smeets JLRM, Xie B, De Chilou C, Cherieux E, Pieters F, et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993;72:1137-41.
25. Twidale N, Sutton K, Bartlett L, Dooley A, Winstanley S, Heddle W, et al. Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. Pacing Clin Electrophysiol 1993;16:1275-84.
26. Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994;74:242-6.
27. Edner M, Caidahl K, Bergfeldt L, Darpö B, Edvardsson N, Rosenqvist M. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J 1995;74:261-7.
28. Gosselink ATM, Bijlsma EB, Landsman MJL, Crijns HJGM, Lie KI. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation. Eur Heart J 1994;15:1368-72.
29. Van Gelder IC, Crijns HJGM, Blanksma PK, Landsman MJL, Posma JL, Van Den Berg MP, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993;72:560-6.
30. Francis GS. Hemodynamic and neurohumoral responses to dynamic exercise: normal subjects versus patients with heart disease. Circulation 1987;76(suppl VI):12-17.
31. Van Den Berg MP, Crijns HJGM, Gosselink ATM, Van Den Broek SAJ, Hillege HJ, Van Veldhuisen DJ, et al. Chronotropic response to exercise in patients with atrial fibrillation: relation to functional state. Br Heart J 1993;70:150-3.
32. Schiebinger RJ, Linden J. Effect of contraction frequency on atrial natriuretic peptide secretion. Am J Physiol 1986;251:H1095-9.
33. Seino Y, Shimai S, Ibuki C, Itoh K, Takano T, Hayakawa H. Disturbed secretion of atrial natriuretic peptide in patients with persistent atrial standstill. J Am Coll Cardiol 1991;18:459-63.
34. Sanfilipo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990;82:792-7.
35. Flaker GC, Blackshear JL, McBride R, Kronmal R, Halperin JL, Hart RG, on behalf of the Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32.
36. Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pedersen WR. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994;74:884-9.
37. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989;63:925-9.
38. Van Den Berg MP, Van Veldhuisen DJ, Crijns HJGM, Lie KI. Reversion of tachycardiomyopathy after β-blocker [letter]. Lancet 1993;341:1667.